Fat lowers fat: purified phospholipids as emerging therapies for dyslipidemia

Area of Science:

• Biochemistry
• Nutritional Science
• Cardiovascular Medicine

Background:

• Dyslipidemia is a primary risk factor for coronary heart disease (CHD), with significant residual risk remaining even after statin therapy.
• Novel therapeutic agents are needed to enhance high-density lipoprotein (HDL) and apolipoprotein A-I (apo A-I) for improved reverse cholesterol transport.
• Phospholipids are essential fats with diverse roles, and their supplementation has shown potential in managing cardiovascular disorders.

Purpose of the Study:

• To review in-vitro, in-vivo, and clinical evidence on the anti-dyslipidemic effects of key dietary phospholipids.
• To explore the mechanisms by which phospholipids influence lipoprotein metabolism and cholesterol levels.
• To assess the potential of phospholipids as an alternative or adjunctive therapy for dyslipidemia.

Main Methods:

• Literature review of in-vitro, in-vivo, and clinical studies.
• Analysis of research on phosphatidylcholine, phosphatidylethanolamine, and phosphatidylinositol.
• Examination of studies investigating phospholipid effects on cholesterol absorption, biliary excretion, and gene expression related to lipid metabolism.

Main Results:

• Dietary phospholipids can reduce serum and hepatic cholesterol and triglyceride levels.
• Supplementation with phospholipids has been shown to increase high-density lipoprotein cholesterol (HDL-C) and apolipoprotein A-I (apo A-I) levels.
• Phospholipids modulate key enzymes and transcriptional factors involved in lipoprotein metabolism, reduce intestinal cholesterol absorption, and enhance biliary cholesterol excretion.

Conclusions:

• Dietary phospholipids, particularly phosphatidylinositol, demonstrate significant anti-dyslipidemic effects.
• Phospholipids offer a safe and biocompatible strategy for managing dyslipidemia.
• Phospholipid supplementation represents a promising novel approach for alternative or adjunctive therapy in cardiovascular disease management.